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INTRODUCTION 
 Low density lipoproteins (LDL) comprise multiple sub-
classes with discrete size and density, different physico-
chemical composition and metabolic behaviour. Ultracentri-
fugation and electrophoretic techniques have identified up to 
7 distinct LDL subclasses. It has been suggested that there 
are parallel metabolic channels within the de-lipidation cas-
cade from very-low density lipoprotein (VLDL) to LDL and 
a metabolic relationship between large VLDL particles and 
small LDL particles has been demonstrated using stable iso-
topes in subjects with a predominance of small dense (sd) 
LDL. These studies have not yet identified the specific pre-
cursors of individual LDL subclasses. However, data from 
animal models suggest that separate pathways may be re-
sponsible for the generation of distinct LDL particles. Fur-
ther, dietary intervention studies have shown inverse associa-
tions between changes in large and small LDL, as well as 
between changes in medium sized and very small LDL 
which raise the possibility of precursor-product relationships 
between distinct LDL subclasses. 
 The activity of lipolytic enzymes has been linked to LDL 
size: reduced lipoprotein lipase (LpL) activity and increased 
hepatic lipase (HL) activity have been shown in subjects  
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with a predominance of sdLDL. Elevated plasma triglyc-
erides (TGs) seem to be the main determinant of LDL sub-
class distribution. Indeed, the formation of sdLDL particles 
is mostly observed in hypertriglyceridaemic state, a condi-
tion that promotes an increased transfer of TGs from TG-rich 
lipoproteins to LDL and high density lipoprotein (HDL) par-
ticles in exchange of cholesterol esters (CE) through the ac-
tion of cholesterol ester transfer protein (CETP). These proc-
esses lead to the generation of VLDL particles enriched in 
CE and smaller, TG-rich LDL particles that are good sub-
strates for HL. As a consequence, the value of sdLDL as a 
predictor of vascular risk is usually reduced when TG levels 
are taken into account. Future studies on diet-gene interac-
tions affecting LDL subclasses may contribute to the under-
standing of mechanisms underlying the inter-individual vari-
ability in LDL subclass distribution. 
CLINICAL EVIDENCE FOR THE SIGNIFICANCE OF 
sdLDL 
 Several lines of evidence suggest that the quality of LDL 
influences cardiovascular risk. To date, the magnitude and 
independence of the association of sdLDL with cardiovascu-
lar disease (CVD) has been tested in more than 50 studies, 
including cross-sectional and prospective epidemiologic as 
well as clinical intervention trials. The majority of these tri-
als demonstrate a significant association of sdLDL with in-
creased CVD risk. Several mechanisms have been proposed 
to explain the enhanced atherogenicity of sdLDL. sdLDL 
may infiltrate arterial tissue more easily than larger LDL. In 
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addition, smaller LDL particles may have decreased recep-
tor-mediated uptake into cells, and express increased affinity 
for proteoglycan. Furthermore, oxidative susceptibility in-
creases and antioxidant capacity is diminished with decreas-
ing LDL size. Altered properties of the surface lipid layer 
associated with a reduced content of free cholesterol and 
increased content of polyunsaturated fatty acids might con-
tribute to enhanced oxidative susceptibility of sdLDL.  
 Increased levels of sdLDL are a feature of subjects at 
very-high CVD risk, such as those with coronary heart dis-
ease (CHD) and type 2 diabetes, as well as those with clini-
cal forms of non-coronary atherosclerosis. Furthermore, re-
cent studies have suggested that sdLDL may be a marker for 
the diagnosis and severity of the metabolic syndrome. Fi-
nally, evidence from angiographic clinical trials indicates 
that treatment benefit was related to a decrease in sdLDL 
particles. These studies include the St. Thomas Atherosclero-
sis Regression Study (STARS), the Monitored Atherosclero-
sis Regression Study (MARS), the Stanford Coronary Risk 
Intervention Project (SCRIP) and the Familial Atherosclero-
sis Treatment Study (FATS). 
MEASUREMENT OF SMALL DENSE LDL 
 In view of the technical difficulties in establishing the 
‘best’ method for separating LDL subclasses in terms of ana-
lytical and diagnostic performance, the choice of method will 
depend, to a large extent, on the availability of equipment, 
expertise to run and interpret the test and the specific ex-
perimental requirements. Under these considerations, the 
techniques fall into 3 categories. The bench or ‘reference’ 
methods of analytical and density gradient ultracentrifuga-
tion and gradient gel electrophoresis that provide high reso-
lution have low throughput and are labour intensive. Alterna-
tively, if large cohorts of samples need to be analysed with-
out the facility of a laboratory or cost restraints, then the 
commercial companies, LipoScience
©
 (nuclear magnetic 
resonance assay), Berkeley HeartLab
©
 (gradient gel electro-
phoretic assay) or Atherotech
©
 (ultracentrifugation assay) all 
provide reliable and standardised services. Finally, if the aim 
is to establish an ‘in-house’ method with high throughput 
and an acceptable degree of standardisation, then the com-
mercially available tests such as LipoPrint
©
 (gradient gel 
electrophoretic assay) or the newer precipitation assay for 
sdLDL (differential precipitation assay), both represent vi-
able options. 
EFFECTS OF TREATMENT ON sdLDL LEVELS 
 This document considers the effect of lipid lowering 
drugs as well as other pharmacological interventions on 
sdLDL. The effects of lifestyle measures are also discussed.  
CONCLUSIONS 
 There is considerable evidence that sdLDL contribute to 
the pathogenesis of atherosclerosis and accelerate its pro-
gression. Further work is required to provide simpler faster 
assays for sdLDL and also to standardise these assays. In-
deed, there is still no universal agreement on what represents 
the reference or ‘gold’ standard for the assessment of LDL 
subclasses. Each method determines different characteristics 
of the LDL particles (e.g. density, size, electrophoretic mo-
bility), thus complicating the interpretation of studies that 
have used different methods. 
 Measurement of sdLDL may have a role in clinical prac-
tice in the monitoring of patients with hypertriglyceridaemia 
beyond that provided by LDL-cholesterol and possibly also 
non-HDL-cholesterol and apolipoprotein B. There is a need 
to establish the clinical relevance of decreasing sdLDL frac-
tions selectively with little effect on the buoyant fractions vs 
decreasing all fractions to a similar extent. The latter situa-
tion (e.g. using a statin) would reduce total LDL-cholesterol 
more considerably than a fibrate (a drug class which would 
more specifically target sdLDL). All these effects may de-
pend on the population studied, their baseline lipid profile 
and the drug (and dose) used. 
 The reference for complete text of the consensus state-
ment is [1]. 
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